Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Stockpiled H5 Influenza Vaccines with AS03 or MF59 Adjuvants
NCT03497845Phase 2Completed
- Sponsor
- Biomedical Advanced Research and Development Authority
- Start
- Mar 2018
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Influenza A H5N1 (H5N1) and influenza A virus H5N8 infection (H5N8) (12 arms), sponsored by Biomedical Advanced Research and Development Authority. Primary endpoints: Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series, Number of Systemic Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series and 2 more. Started Mar 2018; status: completed.
02
Conditions
Influenza A H5N1 (H5N1)influenza A virus H5N8 infection (H5N8)
Beyond the preview
Go deeper on NCT03497845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03497845.